Commerce Dashboard

Lupin Pharmaceuticals

Go Back

Lupin Pharmaceuticals

  • Amongst the top 10 generic companies in the world
  • 18 manufacturing sites
  • Products sold in more than 100 countries
  • Its consolidated income stood at Rs 15,858.5 crore (US$ 2.25 billion) in FY20

Lupin Ltd. is a leading pharmaceutical company from India and is amongst the top 10 generic companies in the world. It started its business in 1968 and over the years has become one of the largest pharmaceutical companies in India and the world. Its businesses include formulations, Active Pharmaceutical Ingredients (API), drug delivery systems and biotechnology. In FY20, Lupin’s total sales stood at Rs 15,142.8 crore (US$ 1.72 billion).

Company Website:

2020 Lupin launched the generic version of Bausch Health's Apriso, used in the treatment of ulcerative colitis, in the US market
2019 Lupin launched Adhero, first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease
Received approval for its propranolol Hydrochloride Extended-Release (ER) capsules from Health Canada.
Lupin’s subsidiary in South Africa declared commercial agreement with Creso Pharma

Nagpur facility wins ENR Global Best Project Award

Launched Doxercalciferol Injection, 4 mcg/2 ml multidose vials, for the treatments of secondary hyperparathyroidism in adult patients with CKD on dialysis.

2017 Entered over the counter (OTC) market with launch of Softovac in India
2016 Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc.
2010 Became fifth largest generic player in the US
2004 Commenced US Brands Business with the launch of Suprax
2002 More than 100 patent filings
1993 Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs
1989 Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed
1980 Commissioned first Formulations plant and an R&D center at Aurangabad, Maharashtra
1968 Commenced business


Updated: May, 2019

India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically.